Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

Closed

Programme Category

EU Competitive Programmes

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Identifier Code

HORIZON-HLTH-2023-DISEASE-03-04

Call

Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

Summary

Proposals under this topic should cover viruses for which there are no currently available effective therapeutics or for which the therapeutics available are sub-optimal, and are expected to incorporate state-of-the-art screening technology and innovative approaches to identify new targets for antiviral compound development. Emphasis should be put on the research and development of broad-spectrum antivirals, which may include repurposing of previously approved or in-pipeline drugs. Proposals could also include elucidation of mode-of-action for candidate anti-viral therapeutics.
Proposals should aim to diversify and accelerate the global therapeutic research and development pipeline for emerging and re-emerging viral infections, and to strengthen the current leading role of the EU in therapeutic research and development.

Detailed Call Description

Proposals should address all of the following areas:

  • Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials for testing new or improved anti-viral therapeutics, with a clear regulatory and clinical pathway. Phase IIb/III phase trials will not be supported.
  • Innovative delivery systems and suitable safety profiles for broad use should be considered when possible. Attention should be paid to critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability.
  • Application of novel approaches and widely applicable workflows (e.g. artificial intelligence) for rapid and reliable identification of broad-spectrum anti-viral therapeutics.

Applicants envisaging to include clinical studies should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.

Call Total Budget

€50,00 million

Financing percentage by EU or other bodies / Level of Subsidy or Loan

100%

Contribution per project: between €7,00 and €8,00 million

Thematic Categories

  • Health
  • Research, Technological Development and Innovation

Eligibility for Participation

  • International Organisations
  • Other Beneficiaries
  • Private Bodies
  • Researchers/Research Centers/Institutions

Eligibility For Participation Notes

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

Call Opening Date

12/01/2023

Call Closing Date

13/04/2023

National Contact Point(s)

Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia

Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/

Contact Persons:
George Christou

Scientific Officer
Email: gchristou@research.org.cy

Ioannis Theodorou
Scientific Officer
Telephone: +357 22 205 038
Contact Email: itheodorou@research.org.cy

(Publish Date: 08/02/2023-for internal use only)

EU Contact Point

European Commission, Directorate-General for Research and Innovation

https://ec.europa.eu/info/departments/research-and-innovation_en#contact